Q3 2021

Source filing unavailable

Q3 2021 · —

Revenue

$682.00K

no prior Q3 2020 on file

Net Income

-$7.54M

no prior Q3 2020 on file

EPS Diluted

$0.21

no prior Q3 2020 on file

Operating Income-$7,485,000—

Operating Cash Flowderived-$5,549,000—

Same quarter

Metric	Q3 2021	Q3 2019	Q3 2018	Q3 2017
Revenue	$682.00K	$682.00K	$617.00K	$617.00K
Net Income	-$7.54M	$4.07M	-$4.35M	-$1.97M
EPS Diluted	$0.21	$0.23	$0.30	$0.15

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR